CORT

110.16

2.83% -3.21

Handel nachbörslich: 109.84 -0.32 -0.29%

Corcept Therapeutics Inc (CORT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$113.37

Offen:

$113.17

24-Stunden-Volumen:

849.64K

Relative Volume:

1.25

Marktkapitalisierung:

$11.91B

Einnahmen:

$769.10M

Nettoeinkommen (Verlust:

$46.67M

KGV:

314.74

EPS:

0.35

Netto-Cashflow:

$119.79M

1W Leistung:

-9.10%

1M Leistung:

-1.48%

6M Leistung:

+150.59%

1J Leistung:

+38.62%

1-Tages-Spanne:

$107.79

$113.64

1-Wochen-Bereich:

$107.79

$122.81

52-Wochen-Spanne:

$28.66

$126.38

Corcept Therapeutics Inc Stock (CORT) Company Profile

Firmenname

Corcept Therapeutics Inc

Sektor

Healthcare (1052)

Branche

Biotechnology (594)

Telefon

650.688.8803

Adresse

101 REDWOOD SHORES PARKWAY, REDWOOD CITY

Mitarbeiter

730

Twitter

Nächster Verdiensttermin

2026-11-03

Neueste SEC-Einreichungen

CORT's Discussions on Twitter

Compare CORT vs VRTX, MRNA, REGN, ARGX, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
CORT Corcept Therapeutics Inc	110.16	11.91B	769.10M	46.67M	119.79M	0.35
VRTX Vertex Pharmaceuticals Inc	499.74	126.66B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	218.01	87.04B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	790.74	81.41B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	819.14	51.51B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	369.06	41.75B	5.76B	514.49M	1.10B	4.4813

Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-08-18	Fortgesetzt	Truist	Buy
2026-07-27	Herabstufung	Wolfe Research	Peer Perform → Underperform
2026-05-13	Hochstufung	UBS	Neutral → Buy
2026-03-26	Hochstufung	Wolfe Research	Underperform → Peer Perform
2025-12-31	Herabstufung	Wolfe Research	Peer Perform → Underperform
2025-12-16	Eingeleitet	UBS	Neutral
2025-11-18	Eingeleitet	Wolfe Research	Peer Perform
2023-11-06	Hochstufung	Truist	Hold → Buy
2023-04-11	Eingeleitet	SVB Securities	Market Perform
2023-04-04	Eingeleitet	Piper Sandler	Overweight
2023-02-15	Herabstufung	Jefferies	Buy → Hold
2022-08-01	Herabstufung	Truist	Buy → Hold
2022-07-27	Hochstufung	Jefferies	Hold → Buy
2022-06-27	Fortgesetzt	Canaccord Genuity	Buy
2022-02-02	Eingeleitet	Canaccord Genuity	Buy
2022-01-28	Eingeleitet	Truist	Buy
2020-08-05	Herabstufung	Jefferies	Buy → Hold
2019-09-24	Eingeleitet	Jefferies	Buy
2019-09-06	Eingeleitet	H.C. Wainwright	Buy
2019-02-04	Herabstufung	B. Riley FBR	Buy → Neutral
2018-08-10	Bestätigt	Stifel	Hold
2018-05-31	Herabstufung	Stifel	Buy → Hold
2018-03-09	Eingeleitet	B. Riley FBR, Inc.	Buy
2017-08-31	Eingeleitet	Stifel	Buy
2017-02-02	Eingeleitet	Ladenburg Thalmann	Buy
2015-04-21	Eingeleitet	FBR Capital	Outperform
2014-01-13	Herabstufung	Stifel	Buy → Hold
2013-08-09	Herabstufung	Janney	Buy → Neutral
2013-08-09	Herabstufung	Ladenburg Thalmann	Buy → Neutral
2012-02-21	Bestätigt	JMP Securities	Mkt Outperform
2010-01-06	Hochstufung	Ladenburg Thalmann	Neutral → Buy
2008-07-17	Eingeleitet	Rodman & Renshaw	Mkt Outperform
2007-06-21	Hochstufung	Punk, Ziegel & Co	Mkt Perform → Accumulate

Alle ansehen

Corcept Therapeutics Inc Aktie (CORT) Neueste Nachrichten

Oct 16, 2026

Buy 5 Top-Ranked Non-Tech Nasdaq Stocks to Maximize Q4 Gains - Zacks Investment Research

Oct 16, 2026

Oct 15, 2026

3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge - Zacks Investment Research

Oct 15, 2026

FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer - Zacks Investment Research

Oct 15, 2026

Here's Why You Should Add EYPT Stock to Your Portfolio Now - Zacks Investment Research

Oct 15, 2026

RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a Week - Zacks Investment Research

Oct 15, 2026

Oct 14, 2026

LQDA Settles UTHR Disputes for $380.7M, Limits Yutrepia Label - Zacks Investment Research

Oct 14, 2026

Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research

Oct 14, 2026

Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal - Zacks Investment Research

Oct 14, 2026

Oct 13, 2026

BMY Reports Mixed Phase III Trial Results, Stock Down - Zacks Investment Research

Oct 13, 2026

Are Options Traders Betting on a Big Move in Corcept Therapeutics Stock? - Zacks Investment Research

Oct 13, 2026

Oct 12, 2026

Drugmaker Corcept seeks to bar ex-judge's views in Teva antitrust case - Reuters

Oct 12, 2026

Prime Medicine Stock Rallies Nearly 26% in a Month: Here's Why - Zacks Investment Research

Oct 12, 2026

PMVP Stock Rises 19% in 3 Months: Here's What You Need to Know - Zacks Investment Research

Oct 12, 2026

Oct 10, 2026

Corcept Therapeutics Inc (HTD.DU) Stock Forum & Discussion - Yahoo! Finance Canada

Oct 10, 2026

Oct 09, 2026

Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Erasca, Inc. (ERAS), DICK’S Sporting Goods, Inc. (DKS), Corcept Therapeutics Incorporated (CORT), and Charter Communications, Inc. (CHTR) - Supply Chain Digital

Oct 09, 2026

Oct 08, 2026

Piper Sandler Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail

Oct 08, 2026

Corcept Therapeutics Incorporat (CORT) Stock Forecasts - Yahoo Finance

Oct 08, 2026

Oct 06, 2026

Corcept Therapeutics Insider Sold Shares Worth $2,906,601, According to a Recent SEC Filing - Yahoo Finance

Oct 06, 2026

Corcept Therapeutics (NasdaqCM:CORT) Stock Forecast & Analyst Predictions - Simply Wall Street

Oct 06, 2026

Oct 05, 2026

Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com India

Oct 05, 2026

Form 4 Corcept Therapeutics Incorporated For: 5 October By Investing.com - Investing.com Nigeria

Oct 05, 2026

Corcept Therapeutics president Sean Maduck sells $2.9 million in stock By Investing.com - Investing.com Australia

Oct 05, 2026

Corcept Therapeutics president Sean Maduck sells $2.9 million in stock - Investing.com

Oct 05, 2026

Corcept Therapeutics president sells $967k in shares - Investing.com

Oct 05, 2026

Corcept Therapeutics chief accounting officer sells $1.16m - Investing.com

Oct 05, 2026

Corcept Therapeutics Oncology President Reports Stock Option Exercise and Sales in Form 4 Filing - Kalkine Media

Oct 05, 2026

Corcept Therapeutics' Sean Maduck Executes Stock Option Exercises and Sells Shares Under 10b5-1 Plan - Kalkine Media

Oct 05, 2026

100,000 stock options awarded to Corcept (CORT) officer vest over four years, subject to continued service. - Stock Titan

Oct 05, 2026

An officer reports 12,191 shares, including unvested awards, and four option positions at Corcept (CORT). - Stock Titan

Oct 05, 2026

The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Zacks Investment Research

Oct 05, 2026

Corcept Therapeutics Incorporated (CORT) Stock Price, News, Quote & History - Yahoo! Finance Canada

Oct 05, 2026

The Zacks Analyst Blog Highlights Abbott, Corcept, Precigen and Bausch Health Companies - Yahoo Finance

Oct 05, 2026

Oct 02, 2026

Corcept Therapeutics Inc. R (HTD.DU) Q1 FY2026 earnings call transcript - Yahoo Finance

Oct 02, 2026

4 Low-Beta Healthcare Stocks to Buy Amid Fears of Another Rate Hike - Zacks Investment Research

Oct 02, 2026

Oct 01, 2026

After a $1.13M September sale, Corcept (CORT) officer proposes another share sale. - stocktitan.net

Oct 01, 2026

Sep 29, 2026

Non-controlling/minority interest of Corcept Therapeutics Incorporated. – HAN:HTD - TradingView

Sep 29, 2026

Sep 28, 2026

Corcept Therapeutics (CORT) business chief gifts shares; two custodial accounts acquire 5,000 each - stocktitan.net

Sep 28, 2026

Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Nigeria

Sep 28, 2026

Corcept Therapeutics’ oncology president sells $29,842 in stock - Investing.com

Sep 28, 2026

Form 4 Corcept Therapeutics Incorporated For: 28 September By Investing.com - Investing.com Canada

Sep 28, 2026

Sep 25, 2026